Hyperfine MRI for Detecting Brain Injury in Pediatric ECMO Patients
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the Hyperfine, Swoop Portable MR Imaging System, Swoop System treatment for detecting brain injury in pediatric ECMO patients?
Is the Hyperfine MRI system safe for use in humans?
Research shows that the Hyperfine MRI system, also known as the Swoop Portable MR Imaging System, is safe for use in both adults and children, including those in intensive care settings. It has been used safely in patients on ECMO (a machine that helps with heart and lung function) and with other medical devices, without any adverse effects from the MRI itself.15678
How is the Hyperfine MRI treatment different from other treatments for detecting brain injury in pediatric ECMO patients?
The Hyperfine MRI, also known as the Swoop Portable MR Imaging System, is unique because it is a portable MRI system that can be used at the bedside, making it easier to perform brain scans in critical care settings like the neonatal intensive care unit (NICU). This is different from traditional MRI machines, which are large and require patients to be transported to a separate imaging department.123910
What is the purpose of this trial?
The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.
Research Team
Jessica Wallisch, MD
Principal Investigator
Children's Mercy Kansas City
Eligibility Criteria
This trial is for pediatric patients aged 0-17 years who are receiving ECMO support due to conditions like brain injury from lack of oxygen, stroke, or trauma. They must be in the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or Neonatal Intensive Care Unit.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Perform bedside MRI in pediatric ECMO patients within 24 hours of cannulation and weekly until decannulation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Hyperfine
Hyperfine is already approved in United States, European Union, Canada, United Kingdom for the following indications:
- Brain imaging
- Brain imaging
- Brain imaging
- Brain imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Mercy Hospital Kansas City
Lead Sponsor